Collegium to Showcase Two PainConnect Posters on Buprenorphine Nonmedical Use and Urine Testing
Collegium Pharmaceutical will present two real-world data posters on its pain portfolio at the American Academy of Pain Medicine’s PainConnect meeting in Salt Lake City on March 6. The studies examine rates of nonmedical buprenorphine use versus other opioids and illicit drug presence in urine among pain clinic patients.
1. Conference Presentation Details
Collegium Pharmaceutical will present two real-world data posters at the American Academy of Pain Medicine’s PainConnect meeting in Salt Lake City, Utah, on March 6 during the organization’s March 5-8 event.
2. Poster Abstracts
Abstract #27 examines the rate and frequency of nonmedical use of buprenorphine versus other opioids for pain treatment, while Abstract #28 reports on the presence of illicit drugs in urine tests among pain clinic patients treated with buprenorphine or full agonist opioids, both presented by Jody L. Green, PhD.
3. Clinical Implications
The real-world data posters aim to provide clinical insights into buprenorphine’s safety and use patterns, supporting evidence-based pain management decisions and potentially informing prescribing practices.
4. Impact on Pain Portfolio
These analyses reflect Collegium’s focus on generating evidence for its differentiated pain medications, which may bolster the company’s positioning in the extended-release opioid market and support further adoption of Belbuca.